Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that develops systemically-administered immunotherapies for oncology and infectious diseases. The company's core technology is its proprietary Decoy platform, which is based on the hypothesis that efficient activation of the immune system requires a multi-targeted package of immune-activating signals. The platform utilizes single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria to produce a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR), and Stimulator of interferon genes (STING) agonist. This approach is designed to safely elicit a broad immune response by activating both innate and adaptive cellular immune pathways without causing severe toxicity.
The company's lead clinical candidate, Decoy20, is being evaluated in Phase 1/1b clinical trials for the treatment of advanced solid tumors, including colorectal, hepatocellular, and pancreatic carcinomas, as well as non-Hodgkin's lymphomas. Decoy20 is also being studied for its potential to treat chronic viral infections, such as hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Indaptus is currently conducting combination trials, evaluating Decoy20 alongside PD-1 checkpoint inhibitors like tislelizumab to induce solid tumor regression.
As a pre-revenue, clinical-stage biotechnology company, Indaptus Therapeutics does not currently generate product revenues and relies on equity financings and private placements to fund its research and development activities. The company operates primarily in the United States and collaborates with academic institutions and contract research organizations to advance its clinical pipeline.
